VVOS Share Price Performance
US$2.13
-1.53 (-41.80%)
67.2% undervalued intrinsic discount
US$6.50
Fair Value
Price US$2.13
AnalystHighTarget US$6.50
AnalystConsensusTarget US$5.83
AnalystLowTarget US$4.00
Fair ValueUS$6.50
Share Pricen/a
Vivos Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
VVOS Community Narratives
AN
Fair Value US$6.5 67.2% undervalued intrinsic discount
Rising Sleep Apnea Prevalence Will Accelerate Noninvasive Treatment Expansion
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$5.83 63.5% undervalued intrinsic discount
FDA Clearance And New Deployments Will Expand Non-Invasive Sleep Care
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$4 46.8% undervalued intrinsic discount
Rising Debt And Regulatory Risks Will Limit Healthcare Expansion
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
FDA Clearance And New Deployments Will Expand Non-Invasive Sleep Care
Key Takeaways New regulatory clearance and market preferences are removing adoption barriers, fueling revenue and margin growth through expanded treatment options for sleep apnea. Strategic expansion, scalable service models, and a shift to recurring revenue streams are positioning the company for sustainable, high-margin earnings and broader market reach.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$5.83
63.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
56.46% p.a.
Profit Margin
5.24%
Future PE
22.24x
Price in 2028
US$4.14
Rising Sleep Apnea Prevalence Will Accelerate Noninvasive Treatment Expansion
Key Takeaways Surging patient demand and rapid operational rollout support potential for significantly higher revenue, margin expansion, and accelerated positive cash flow beyond current expectations. Clinically validated solutions, experienced leadership, and streamlined workflows position the company for rapid, scalable growth and sustained, high-margin recurring revenue.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6.5
67.2% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
53.82% p.a.
Profit Margin
5.27%
Future PE
25.78x
Price in 2028
US$4.32
Rising Debt And Regulatory Risks Will Limit Healthcare Expansion
Key Takeaways Growing losses, high debt, and reliance on short-term financing threaten sustainability and value, increasing pressure for costly fundraising or debt that suppress earnings. Shifting consumer demand, regulatory hurdles, and strong competitors limit growth potential for Vivos's treatments, jeopardizing expansion and market position.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$4
46.8% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
30.27% p.a.
Profit Margin
5.39%
Future PE
25.55x
Price in 2028
US$2.66
Trending Discussion
Recently Updated Narratives
AN
VVOS: Significant Clinical Findings Will Drive Upside in 2024
Fair Value: US$5.83 63.5% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Debt And Regulatory Risks Will Limit Healthcare Expansion
Fair Value: US$4 46.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Sleep Apnea Prevalence Will Accelerate Noninvasive Treatment Expansion
Fair Value: US$6.5 67.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vivos Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.90
- 55.73%
- -98.76%
- 344.3%
About VVOS
- Founded
- 2016
- Employees
- 262
- CEO
- WebsiteView website
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
